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Human pluripotent stem cells (hPSCs), including
embryonic stem cells and induced pluripotent stem
cells, are potentially useful in regenerative therapies
for heart disease. For medical applications, clinical-
grade cardiac cells must be produced from hPSCs
in a defined, cost-effective manner. Cell-based
screening led to the discovery of KY02111, a small
molecule that promotes differentiation of hPSCs
to cardiomyocytes. Although the direct target of
KY02111 remains unknown, results of the present
study suggest that KY02111 promotes differentiation
by inhibiting WNT signaling in hPSCs but in a manner
that is distinct from that of previously studied WNT
inhibitors. Combined use of KY02111 and WNT
signalingmodulators produced robust cardiac differ-
entiation of hPSCs in a xeno-free, defined medium,
devoid of serum and any kind of recombinant cyto-
kines and hormones, such as BMP4, Activin A, or
insulin. The methodology has potential as a means
for the practical production of human cardiomyo-
cytes for regeneration therapies.
INTRODUCTION
Human pluripotent stem cells (hPSCs), including embryonic
stem cells (hESCs) and induced pluripotent stem cells (hiPSCs),
can proliferate indefinitely in an undifferentiated state and differ-
entiate into many types of cells in human tissues, including the
heart (Chien et al., 2004; Irion et al., 2008; Lutolf et al., 2009).
Therefore, hPSCs are potentially useful in cell-based therapies
for heart disease (Chien et al., 2008; Hansson et al., 2009;1448 Cell Reports 2, 1448–1460, November 29, 2012 ª2012 The AutLaflamme and Murry, 2011; Menasche´, 2009; Passier et al.,
2008; Segers and Lee, 2008). Efficient production of functional
cardiac cells from hPSCs is required for cell-based therapy.
Multiple cardiac differentiation methods have been described,
and these procedures need animal cells, fetal bovine serum
(FBS), or various cytokines (Burridge et al., 2012; Laflamme
andMurry, 2011; Rajala et al., 2011). However, an efficient single
method cannot always be applied to all hPSC lines because of
the differences in differentiation propensity among cell lines
(Osafune et al., 2008). Recently, a universal cardiac differentia-
tion method that is independent of hPSC lines was reported,
but it requires FBS or human serum for highly efficient differenti-
ation (Burridge et al., 2011). Another study using serum-free
medium showed that optimal cytokine concentrations for
cardiac induction differ among individual hPSC lines (Kattman
et al., 2011). However, use of recombinant cytokines is not
cost effective for large-scale production, and the use of serum
needs be avoided for clinical use because of the potential risk
for disease infection.
Small molecules have great potential as substitutes for
recombinant cytokines and unknown factors in serum (Xu
et al., 2008), and they are suitable for making defined media
for large-scale culture. To date, small molecules have been
used to activate or inhibit signaling pathways, such as WNT or
TGF-b signaling (Chen et al., 2009; Ichida et al., 2009), or to regu-
late the expression of genes instead of transcription factors
(Kamisuki et al., 2009; Sato et al., 2006). A number of small
molecules have been examined or screened for promotion of
differentiation: a BMP signaling inhibitor, a p38MAPK signaling
inhibitor, a WNT signaling activator, and WNT signaling in-
hibitors were all reported to promote cardiac differentiation
(Graichen et al., 2008; Hao et al., 2008; Naito et al., 2006; Qyang
et al., 2007; Ren et al., 2011; Wang et al., 2011; Willems et al.,
2011). However, these chemical treatments resulted in only
10%–60% differentiation to cardiomyocytes (Naito et al., 2006;hors
Qyang et al., 2007; Ren et al., 2011; Wang et al., 2011; Willems
et al., 2011). Hence, a small molecule that produces more effi-
cient differentiation is needed for clinical applications.
An enrichment of hPSC-derived cardiomyocytes as well as an
increase in differentiation efficiency are important. Recently,
enrichment procedures without using genetic modifications
were reported by Dubois et al. (2011) and Hattori et al. (2010).
These methods utilize fluorescence-activated cell sorting
(FACS) technology based on mitochondria content or cell
surface molecules. However, a FACS-based enrichment proce-
dure would be time consuming for the preparation of a large
amount of cells.
In this study, we report a small molecule promoting cardiac
differentiation of hPSCs. By using this chemical, xeno-free and
cytokine-free cardiac differentiation was achieved. Moreover,
functional cardiomyocytes derived from hPSCs were enriched
(up to 98%) by a simple floating culture protocol without FACS
procedures.
RESULTS
Discovery and Characterization of KY02111
To identify small molecules that efficiently promote cardiomyo-
cyte differentiation from hPSCs, we established a high-content
analysis (HCA) system, using monkey ESCs that express EGFP
driven by human aMHC promoter (Figure 1A). The chemical-
screening protocol for the detection of an EGFP signal is
described in Experimental Procedures. We identified one mol-
ecule, N11474, that significantly enhanced the values of HCA
parameters compared to the control (Student’s t test, p = 0.015).
During chemical screening, monkey ESCs were treated with
1–5 mM of small molecules for 8 days (days 6–14). To determine
the period during which N11474 effectively promotes differenti-
ation, we used several treatment patterns and measured the
total signal intensity of aMHC promoter-driven EGFP on day
14 (Figure 1B). N11474 treatment on days 6–10 was similarly
effective to the screening protocol, and treatment after day 8
(days 8–12 or days 10–14) was less effective. Treatment on
days 4–8 maximized the increase in GFP expression, whereas
treatment on days 0–4 completely repressed GFP expression.
The treatment with a higher concentration (10 mM) revealed
similar results and more efficacious increase of GFP intensity
on days 4–8. These results suggested that in monkey ESCs,
N11474 acts as an inhibitor in the early phase (days 0–4) and
as a promoter in the middle phase (days 4–8) of cardiac
differentiation.
We chemically synthesized analogs of N11474 (Figures S1A
and S1B) and assayed their ability to promote cardiac differenti-
ation of monkey ESCs. Structure-activity relationship studies
revealed that substitution of the methoxy group at the benzo-
thiazole ring with an electron-withdrawing group, and adjust-
ment of the length of the methylene linker, greatly improved
biological activity, resulting in the molecule KY02111 (Figures
1C, 1D, and S1C). This drug-like small molecule promoted
cardiac differentiation 73 times more effectively than the
DMSO control and 7.4 times more effectively than N11474.
Time course experiments using IMR90-1 hiPSCs showed that
beating colonies emerged on day 8 and increased in numberCell Reuntil day 12 under adherent conditions (Figure 1E). When
all the colonies were collected on day 15 as described in
Experimental Procedures, the subsequent proportion of beating
colonies evidently increased up to 90% in floating culture,
probably due to reduced mechanical inhibition (Otsuji et al.,
2010). This result suggested that a large proportion of cell
colonies emerged in the cardiac differentiation protocol using
KY02111 might be cardiac beating colonies. The cardiac colo-
nies continued beating until at least day 50.
The general applicability of KY02111’s activity was examined
with a variety of primate and rodent PSCs (Figure 1F). KY02111
increased the ratio of beating cardiac colonies as much as
70%–94% in cell aggregates of two hESC lines (KhES-1 and
KhES-3), four hiPSC lines (253G1, IMR90-1, IMR90-4, and
RCHIPC0003), and a mouse ESC line (R1).
Characterization of Cardiomyocytes Produced
by KY02111
Immunocytochemical analysis of day 30 cardiac colonies, which
were switched to floating culture on day 15, showed that approx-
imately 73%–85% of IMR90-1 hiPSCs treated with KY02111
expressed the cardiac markers, cardiac troponin T (cTnT),
aActinin, or NKX2.5, whereas only a few DMSO-treated cells
were positive for the markers (Figures 2A and 2B). The cardiac
pacemaker marker, HCN4, was expressed in 16% of KY02111-
treated cells, whereas the ratio of Vimentin-positive cells (fibro-
blasts) decreased 3.3-fold (Figure 2B). SMA, a marker of smooth
muscle, was almost undetectable in KY02111-treated cells
(data not shown). These results suggested that hPSC-
derived cardiomyocytes can be enriched by simply harvesting
KY02111-induced cell colonies, without resorting to cell-sorting
procedures. Real-time PCR analysis on days 15 and 30 showed
that KY02111-induced cardiomyocytes (KY-CMs) expressed the
cardiac markers, aMHC, NKH2.5, and HCN4, and that all of the
ion channel genes examined were expressed at levels similar
to those of adult heart tissue (Figure 2C).
FACS analysis revealed that approximately 60% or 8% of day
30 KY-CMs were MLC2v-positive mature ventricular cardiomyo-
cytes or MLC2v/MLC2a double-positive immature ventricular
cardiomyocytes, respectively, and that fewMLC2a-positive cells
were detected (Figure 2D), suggesting that the majority of
KY-CMs are ventricular cardiomyocytes.
Electrophysiological analysis by the whole-cell patch-clamp
method was used to examine whether day 30 KY-CMs are
functional cells. Action potential properties indicated that the
population of KY-CMs included ventricular cells and pacemaker
cells (Figure 2E). The properties of voltage-dependent Ca2+, Na+,
and HCN channel currents were examined using the ion channel
blockers, nifedipine, lidocaine, and zatebradine, respectively
(Figures S2A–S2C). The current density-voltage relationships
indicated that KY-CMs were electrophysiologically functional.
Treatment of KY-CMs with HERG channel blocker, E4031, and
KCNQ1 channel blocker, Chromanol293B, increased action
potential duration (APD), which is equivalent to QT prolongation
detected by an electrocardiogram (ECG) (Figure 2F). The
increases in duration of APD90 (APD at 90% repolarization)
were 37.0% ± 11.2% for E4031 treatment, and 42.1% ±
8.8% for Chromanol293B treatment (Figure S2E). Moreover,ports 2, 1448–1460, November 29, 2012 ª2012 The Authors 1449
Figure 1. Identification and Characterization of Small Molecules that Promote Cardiac Differentiation
(A) Schematic of small molecule screening. One hit compound was identified from the chemical library of 9,600 compounds (Murakami et al., 2011), using human
aMHC promoter-driven EGFP transgenic monkey ESCs and a HCA system.
(B) Effective timewindowof hit compound, N11474. The expression level of the DMSO control is 100%. The experiment was independently performed three times
(n = 3). Mean ± SEM. D, day.
(C) Chemical structures of N11474 and KY02111.
(D) Structure-activity relationships of N11474 and related compounds. Transgenic monkey ESCs were treated with 10 mM of chemical compounds. Top graph
shows GFP increase ratio. Green dots in the whole-well images (bottom photos) indicated colonies with GFP signals. Scale bar, 10 mm. The length of carbon
chain that connects the benzothiazole ring to the dimethoxyphenyl ring was important for inducing GFP expression (n = 3). Mean ± SEM.
(E) Time course analysis of cardiac differentiation induced by KY02111. IMR90-1 was treated with 10 mMKY02111. Cardiac colonies were transferred to floating
culture on day 15 (n = 3). Mean ± SEM.
(F) Generality of KY02111 effect on PSC lines. hESC lines (KhES-1 and KhES-3), monkey ESC line (CMK6.4), mouse ESC line (R1), and hiPSC lines (IMR90-1,
IMR90-4, 253G1, and RCHIPC0003) were differentiated into cardiomyocytes by treatment with 10 mM KY02111. The ratio of beating colonies in floating culture
was examined for all PSC lines on day 30 except mouse ESC. Mean ± SEM. n, the number in parentheses.
See also Figure S1.
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Figure 2. Characterization of Cardiomyocytes Derived from hPSCs Treated with KY02111
(A and B) KY02111 promoted the expression of cardiac markers. IMR90-1 hiPSCs were treated with 10 mM KY02111, and then cardiac markers (cTnT, aActinin,
andNKX2.5), pacemakermarker, HCN4, and fibroblast marker, Vimentin, were examined using floating cardiac colonies. (A) The upper and lower images are cells
treated with KY02111 or DMSO, respectively. Scale bar, 100 mm. (B) Immunopositive cell ratio in cells treated with KY02111 (n = 3). Mean ± SEM.
(C) qPCR gene expression analysis of KY-CMs. Total RNAwas extracted from IMR90-1-derived KY-CMs on days 15 and 30 of cardiac differentiation using 10 mM
KY02111. Cardiac marker genes (aMHC, bMHC, cTnT, aActinin, and NKX2.5) and channel genes (HCN4, Nav1.5, Cav1.2, Cav3.2, HERG1b, and KCNQ1) were
highly expressed in KY-CMs. Almost all genes were upregulated at day 30, and their gene expression levels were nearly equal to the gene expression levels of
adult heart tissue, which was considered to be 100% (mean ± SEM; n = 3). All primers used are shown in Table S2.
(D) FACS analysis of KY-CMs. A total of 30,000 cells of IMR90-1-derived KY-CMswere measured in each sample by FACSCanto II. Mean ± SEM; n = 3. The inset
shows representative flow cytometry data. Red indicates MLC2v and/or MLC2a-positive cells. Gray indicates negative controls without the primary antibody.
(E and F) Functionality of KY-CMs. (E) Spontaneous ventricular-like or pacemaker-like action potential (AP) in patch-clamp recordings from day 30 KY-CMs. (F)
Prolongation of APD induced by 100 nM E4031 and 4 mM Chromanol293B.
See also Figures S2 and S3.voltage-dependent K+ currents were suppressed by treatment
with E4031 and Chromanol293B (Figures S2D and S2E). These
results indicated that the KY-CMs expressed functional HERG
and KCNQ1 channels. A drug-induced QT prolongation test,
performed using a microelectrode array (MEA), showed that
ECG-like waves were emitted from KY-CM colonies (Figures
S3A and S3B). Treatment with astemizole, which causes clinical
QT prolongation (Suessbrich et al., 1996), prolonged the Na+-K+Cell Reinterval of the ECG-like waves in a dose-dependent manner
(Figure S3C). Overall, these results indicated that KY-CMs are
electrically and pharmacologically functional.
Inhibition of Canonical WNT Signaling Pathway
by KY02111
To gain insight into how KY02111 promotes cardiac differentia-
tion of hPSCs, gene expression profiles of IMR90-1 hiPSCsports 2, 1448–1460, November 29, 2012 ª2012 The Authors 1451
Figure 3. KY02111 Is a Canonical WNT Signaling Inhibitor
(A) Heatmap of downregulated genes. IMR90-1 hiPSCs were treated with 10 mMKY02111 or DMSO for 12 or 24 hr (KY12hr, KY24hr, DMSO12hr, or DMSO24hr),
and 26 genes were identified. A total of 22 downregulated genes were used to generate the heatmap. Four upregulated genes are shown in Table S1. Red gene
symbols indicate WNT-signaling target genes (see also Table S1).
(B and C) TCF reporter assay using IMR90-1 hiPSCs or HEK293 cells. The effect of KY02111 (KY), XAV939 (XAV), IWP-2 (IWP), or DMSO (Control) was examined.
Wnt3a (60 ng/ml) was added to activate WNT signaling and TCF promoter activity. IWP-2 did not inhibit TCF promoter activities, probably because IWP-2 is an
inhibitor of WNT ligand secretion. n = 3 (B) and n = 3 (C); mean ± SEM. *p < 0.05, **p < 0.01 by Student’s t test.
(D) Comparison of cardiac differentiation promoting activity among chemical and proteinaceous WNT inhibitors. The activity was measured using monkey ESCs
with EGFP gene driven by human aMHC promoter on day 14. The activity level of the DMSO control treatment was considered to be 100%. The small molecule
WNT inhibitors were KY02111, IWP-2, XAV939, and IWR-1. The proteinaceous factors were IGFBP4 (0.2 and 1mg/ml), Dkk1 (0.1 and 0.3 mg/ml), and a mixture of
bFGF, BMP4, VEGF, DKK1, and Activin A (cytokines) (Yang et al., 2008). Mean ± SEM; n = 4. **p < 0.01 by Student’s t test.
See also Figure S4.treated with KY02111 were analyzed using the microarray tech-
nique. KY02111 or DMSO was added to the culture on day 3 of
cardiac differentiation, and the cell population was harvested
after 12 or 24 hr. A total of 22 downregulated genes and four
upregulated genes were identified at both 12 and 24 hr after
KY02111 treatment (Figure 3A; Table S1). Although only a few
genes were extracted by the microarray analysis, perhaps due
to high heterogeneity of the cell population, the microarray
data were validated by qPCR (Figure S4A). When the 22 down-
regulated genes were examined for common transcription
factor-binding sites, using DiRE (Gotea and Ovcharenko,
2008), which can predict distant regulatory elements, TCF4
was predicted as a common transcription factor (Figure S4B).
Of the 22 downregulated genes, 16 (72.7%) were known target
genes of canonical WNT signaling (Table S1). Furthermore, the
effect of KY02111 on WNT target gene expression was very
similar to that of other WNT inhibitors, such as XAV939 and1452 Cell Reports 2, 1448–1460, November 29, 2012 ª2012 The AutIWP-2, but not of BIO, a WNT activator (Figure S4C). These
results suggested that KY02111 inhibits canonical WNT sig-
naling in hPSCs.
The TOPflash assay, a reporter system generally used for
measuring activities of canonical WNT signaling, was used to
confirm that KY02111 is aWNT signaling inhibitor. IMR90-1 cells
or HEK293 cells were transfected with TCF reporter plasmids
and then were treated with Wnt3a along with 1, 3, or 10 mM
of KY02111, XAV939, or IWP-2. Treatment with KY02111 or
XAV939 clearly reduced luciferase activities in both cell lines in
a dose-dependent manner (Figures 3B and 3C). TOPflash results
substantiated that KY02111 is an inhibitor of canonical WNT
signaling.
We next compared the promotion of cardiac differentiation in
transgenic monkey ESCs by KY02111, several chemical or
proteinaceous WNT inhibitors (IWP-2, IWR-1, XAV939, DKK1,
and IGFBP4; Zhu et al., 2008), and a combination of severalhors
cytokines. All of them increased the intensity of the GFP signal
driven by aMHC promoter (Figure 3D). Of them, KY02111 was
most potent at an effective concentration of 10–25 mM. Treat-
ment with KY02111 increased differentiation about 80-fold
compared to the control and did not show toxicity to cells even
at high concentration.
Mechanism of WNT Signaling Inhibition by KY02111
To explore how KY02111 inhibits WNT signaling, we compared
its effect with two WNT inhibitors, IWP-2 and XAV939, which
inhibit O-acyltransferase and tankyrase, respectively (Chen
et al., 2009; Wang et al., 2011). The other known inhibitor,
IWR-1, was not used because the target of IWR-1 is the same
as that of XAV939 (Narwal et al., 2012). The compounds were
used at a concentration of 10 mM, which was sufficient to inhibit
the TCF reporter activity in the TOPflash assay and also to
promote cardiac differentiation (Figures 3B–3D). SW480, a
human colon adenocarcinoma cell, has mutation of adenoma-
tous polyposis coli (APC) gene that stabilizes b-catenin (Morin
et al., 1997). Hence, the basal luciferase activity of SW480 is
very high even without Wnt3a treatment in the TOPflash assay
(Figure 4A). Treatment of KY02111 significantly reduced lucif-
erase activity in SW480 cells, whereas XAV939 and IWP-2 did
not. Furthermore, additional assays were performed using
IMR90-1 cells and HEK293 cells treated by a GSK3b inhibitor
BIO, which prevents b-catenin degradation. Treatment of BIO
along with KY02111 dramatically reduced luciferase activity
induced by BIO, compared to XAV939 and IWP-2 (Figures 4B
and 4C). In addition, we confirmed the dose-dependent effects
of KY02111 across all the TOPflash assays performed (Figures
S5A–S5C).
To evaluate the role of WNT signaling inhibition in cardiac
differentiation, monkey ESCs and hiPSCswere induced to differ-
entiate into cardiomyocytes in the presence of BIO. When BIO
was added along with IWP-2 or XAV939, cardiac differentiation
of monkey ESCs and hiPSCs was completely inhibited, whereas
cardiac differentiation promoted by KY02111 remained unaf-
fected (Figures 4D and 4E). KY02111 overcame the effect
of BIO in a dose-dependent manner (Figures S5D and S5E).
Together with the TOPflash results, these data suggest that the
mechanism of WNT inhibition by KY02111 is different from that
of IWP-2 or XAV939. It appears that KY02111 might be acting
downstream of APC and GSK3b in the canonical WNT signaling
pathway.
Because targets differ among WNT inhibitors, we examined
whether the use of a combination of WNT inhibitors might
enhance differentiation of hPSCs to cardiomyocytes. KY02111
alone produced approximately 80% cTnT-positive cells;
KY02111 in combination with other WNT inhibitors did not
significantly increase differentiation efficiency (Figure S5F).
However, treatment with a combination of WNT inhibitors did
significantly enhance total cell numbers and beating colony
numbers compared to treatment with KY02111 alone and the
combination of XAV989 and IWP-2 (XAV+IWP) (Figures 4F and
S5G). The number of cardiomyocytes produced by day 30
was 80-fold higher in the KY02111 and 130- to 180-fold higher
in the combined treatments (KY+IWP and KY+XAV) than in the
control.Cell ReDefined, Cytokine-free, and Xeno-free Cardiac
Differentiation
When cardiac differentiation in serum-free medium was exam-
ined, two requirements emerged: surface coating with gelatin
or human laminin211, and an addition of 0.4% human serum
albumin or 1%–2% BSA. Nonattached cells were minimally
differentiated into cardiomyocytes, and cell death occurred in
serum-free medium without albumin (data not shown).
Activation of WNT signaling is required for the early phase of
cardiac differentiation in hPSCs. Therefore, the effect of WNT
activators, BIO and CHIR99021 (CHIR), was examined in the
early stage of differentiation, in the absence of BMP4 (Figure 5A).
Although treatment with 2–4 mM CHIR alone increased the
number of cardiac beating colonies, the combined use of
1–2 mM BIO and 4 mM CHIR resulted in more efficient cardiac
differentiation (Figure 5B). Treatment with the optimal concen-
trations of BIO and CHIR on days 0–3 led to an upregulation
(4- 14-fold) of mesodermal marker genes (MSGN1, T, MIXL1,
andNODAL) in IMR90-1 hiPSCs (Figure 5C). Following treatment
with KY02111 alone or in combination with XAV939 (KY+XAV),
beating colonies emerged on days 8–10 (Movie S1). The treat-
ment with these WNT signaling modulators resulted in
84%–98% cTnT-positive cell ratio of floating cardiac colonies
derived from IMR90-1 hiPSCs under both serum-containing
and serum-free, albumin-containing medium culture condi-
tions (Figures 5D and 5E). These results suggest that small
molecule-mediated activation of WNT signaling and endoge-
nous signaling factors are sufficient to induce mesodermal cells
during cardiac differentiation.
Treatment with KY+XAV did not result in significantly different
cTnT-positive cell ratio of floating cardiac colonies compared to
treatment with KY02111 alone (Figure 5D). However, FACS
analysis showed that, under cytokine- and serum-free condi-
tions, treatment with KY+XAV had slightly higher ratio (98.1%)
than treatment with KY02111 alone (90.2%) (Figure 5F). Immu-
nostaining analysis showed, furthermore, that treatment with
KY+XAV produced a higher proportion of cTnT-positive cells
(97.7% ± 0.8%) than KY02111 alone (93.3% ± 4.4%) (Figures
5D and 5E). Thus, the combined use of KY+XAV appears to result
in highly efficient cardiac differentiation of hPSCs.
TreatmentwithKY02111 in the presence of serumgave a lower
cTnT-positive cell ratio of floating cardiac colonies (83.7% ±
8.0%) compared to the treatment with KY02111 in the presence
of albumin (93.3% ± 4.4%) (Figure 5D). The number of beating
colonies and cardiomyocytes was about three times higher in
serum-free KY02111 treatment compared to treatment under
serum-containing conditions (Figure 5G). Similarly, treatment
with KY+XAV without serum enhanced these numbers approxi-
mately 1.5-fold over treatment with serum. These results sug-
gest that FBS might contain factor(s) that inhibits cardiac
induction and/or proliferation of cardiac progenitors.
Additional experiments confirmed that other hPSCs (KhES-3,
H1, H9, RCHIPC0003, and 253G1) efficiently differentiated into
cardiomyocytes in cytokine- and xeno-free, defined medium
containing KY02111, BIO, CHIR, and XAV939. As observed in
IMR90-1 hiPSCs, these treatments enhanced the proportions
of beating colonies and cTnT-positive cells in all the cell lines
tested (Figures 6A and 6B). Immunostaining of aActinin clearlyports 2, 1448–1460, November 29, 2012 ª2012 The Authors 1453
Figure 4. KY02111 and Other WNT Inhibitors Cooperatively Promote Cardiac Differentiation through Distinct Manner of WNT Signaling
Inhibition
(A) TCF reporter assay using SW480 cells. The effect of 10 mMKY02111 (KY), 10 mMXAV939 (XAV), 10 mM IWP-2 (IWP), or DMSO (Control) was examined.Mean ±
SEM; n = 4. **p < 0.01 by Student’s t test.
(B and C) TCF reporter assay using IMR90-1 hiPSCs and HEK293 cells. BIO (3 mM) was added to activate WNT signaling. n = 3 (B) and n = 3 (C); mean ± SEM.
*p < 0.05, **p < 0.01 by Student’s t test.
(D and E) A GSK3b inhibitor did not abolish the effect of KY02111 on cardiac differentiation. Colonies with GFP signal driven by human aMHC promoter were
produced using 10 mMKY, XAV, or IWP treatment, with or without 5 mMBIO. (D) Representative images of the GFP signal (green dots) in whole wells. Images were
captured at day 14. Numbers at bottom left of each image indicate the increase in GFP signal ratio (DMSO = 100%). (E) Proportions of day 30 beating colonies of
IMR90-1 hiPSCs. Mean ± SEM; n = 3.
(F) Cooperative effects of KY02111 with XAV939 or IWP-2. On day 0 of differentiation, 63 106 IMR90-1 cells per well were added to a 6-well plate. Blue bars show
the number of beating cardiac colonies induced by KY, XAV, IWP, KY+XAV, KY+IWP, and XAV+IWP. Each chemical concentration was 10 mM. Red bars show the
total number of cardiomyocytes, calculated by multiplying total cell numbers of all colonies by the ratio of cTnT-positive cells (see Figures S5F and S5G). Mean ±
SEM; n = 4. *p < 0.05, **p < 0.01 for Student’s t test comparing each treatment to KY02111 alone.
See also Figure S5.showed sarcomere structures in cardiomyocytes derived from
IMR90-1 hiPSCs under cytokine- and xeno-free, defined condi-
tion (Figure 6C). Also, electron microscopy revealed the struc-
tural features of hPSC-derived cardiomyocytes, such as the
presence of myofibrils, Z bands, mitochondria, intercalated
disks with desmosomes, and sarcoplasmic reticula (Figures
6D and S6). Cardiac colonies, which were harvested on day
15, continued beating in floating culture (Movie S2). Further-1454 Cell Reports 2, 1448–1460, November 29, 2012 ª2012 The Autmore, the gene expression levels of cardiac markers (aMHC,
aActinin, and NKX2.5) and all of ion channel genes examined
were nearly equal to those of adult heart tissue on both day
15 and day 30 (Figure 6E). Overall, these results showed that
the KY02111 differentiation method, using WNT signal-modu-
lating small molecules and defined medium, effectively
produced a high proportion of functional cardiomyocytes from
hPSCs.hors
DISCUSSION
The present study reports on a small molecule, KY02111 (original
molecule, N11474), that promotes cardiac differentiation and
acts as a WNT inhibitor in hPSCs. The effective window for
treatment with KY02111 is during the middle phase of cardiac
differentiation (days 3–8); treatment during the early phase
(days 0–3) resulted in suppression of cardiac differentiation.
This timing is consistent with previous reports that canonical
WNT signaling is required for induction of cardiac differentiation
or mesoderm induction of hPSCs, and not for later stages of
differentiation (Laflamme and Murry, 2011; Mignone et al.,
2010; Naito et al., 2006; Paige et al., 2010). Results presented
in this study suggest that KY02111 is a WNT inhibitor and
produces more efficient cardiac differentiation than other known
WNT inhibitors. Efficient cardiac differentiation in all eight hPSC
lines examined was achieved using a fixed concentration
of KY02111, indicating that optimization of the differentiation
procedure might not be required or might be relatively simple.
Treatment with KY02111 and other WNT inhibitors, such as
XAV939 and IWP-2, had a cooperative effect, increasing the
number of both cardiomyocytes and beating colonies. The com-
bined use of BIO and CHIR in the early phase of cardiac differen-
tiation, and use of KY+XAV in the middle phase, produced up to
98% cardiomyocytes in cytokine- and serum-free, xeno-free,
defined medium. Thus, these treatments might be useful for
producing cardiomyocytes for cell-based therapy because all
components of defined media are relatively safe and inex-
pensive. However, cell attachment via gelatin or laminin211 is
essential for efficient differentiation, suggesting that mechano-
transduction or integrin signaling from interaction with these
substrates might be important (Jacot et al., 2010).
Serum-free conditions produced greater numbers of cardio-
myocytes in our cardiac differentiation protocol than serum-
containing conditions. Although serum is essential for several
other differentiation methods, it had an inhibitory effect in our
method. Although no inhibitory factors in serum are known,
serum contains insulin, which was reported to be an inhibitor
of cardiac differentiation (Burridge et al., 2011). Our method
requires only small molecules that regulate WNT signaling,
and not exogenous BMP4, Activin A, or bFGF, which are often
used to increase efficiency of cardiac differentiation (Burridge
et al., 2011; Yang et al., 2008). Thus, two WNT activators,
BIO and CHIR, appear to fully lead to cardiac mesoderm
induction.
A very recently published paper reported that known WNT
signaling modulators effectively induced cardiomyocytes in the
defined medium with B27 supplement containing insulin, a few
steroid hormones, and BSA (Lian et al., 2012). Interestingly, their
method predominantly produced MLC2a-positive ventricular
cardiomyocytes without any cardiac pacemaker cells, whereas
our method mainly produced MLC2v-positive/MLC2a-negative
ventricular cardiomyocytes and did include some cardiac pace-
maker cells. This suggests that KY02111 itself, the combination
of small molecules, or the absence of B27 supplement in our
cytokine and xeno-free condition might be able to induce to
generation of MLC2v-positive/MLC2a-negative cardiomyocytes
and pacemaker cells from hPSCs.Cell ReCardiomyocytes derived from hPSCs described in earlier
reports (reviewed in Mummery et al., 2012) were thought to be
immature and similar to human fetal cardiomyocytes because
of the presence of many MLC2v/MLC2a double-positive
ventricular cardiomyocytes with disorganized sarcomeres and
weak HERG channel responses. However, our method mainly
produced MLC2v-positive/MLC2a-negative cardiomyocytes
with well-organized sarcomeres and strong HERG channel
responses, indicating that our method might produce more
mature cardiomyocytes, though complete maturation did not
occur.
The method developed in the present study produced
functional cardiomyocytes. These cells have potential for use
in stem cell-based therapy. They also have potential pharmaceu-
tical applications, e.g., safety screening for detecting side effects
such as drug-inducible QT prolongation (Asai et al., 2010). Large
numbers of cardiomyocytes are required for these applications.
Large-scale KY+XAV-mediated differentiation could potentially
produce a sufficient number of cardiomyocytes from hPSCs.
The method described herein produced 4.2 3 106 cardiomyo-
cytes from approximately 6.0 3 106 cells seeded initially in one
well of a 6-well plate. Although there is room for improvement,
our differentiation method produces safe, functional cardiomyo-
cytes and may provide a practical procedure for cell-based
therapy of heart diseases.
The direct target of KY02111 is still unknown, but results from
this study indicate that KY02111 might function downstream
from GSK3b and APC in b-catenin destruction complex
and suggest that KY02111 may be a powerful tool for not
only cardiac research using hPSCs but also WNT signaling
studies. Future research should identify the direct target of
KY02111.
EXPERIMENTAL PROCEDURES
Culture of hESC, hiPSC, and Monkey ESC
All PSC lines were maintained as described (Suemori and Nakatsuji, 2006).
hESC lines used were KhES-1, KhES-3, H1, and H9 (Suemori et al., 2006;
Thomson et al., 1998). hiPSC lines used were 253G1, IMR90-1, IMR90-4
(Takahashi et al., 2007; Yu et al., 2007), and RCHIPC0003. RCHIPC0003
was established from human fibroblasts by ReproCELL. The monkey ESC
line was CMK6.4 (Suemori and Nakatsuji, 2006). The hESC lines were used
in conformity with the Guidelines for Derivation and Utilization of Human
Embryonic Stem Cells of the Ministry of Education, Culture, Sports, Science,
and Technology (MEXT) of Japan.
Transgenic Monkey ESC Line
The human aMHC promoter-driven EGFP-expressing vector was constructed
in the previous study (Otsuji et al., 2010). The linearized vector was introduced
into CMK6.4 monkey ESCs by electroporation. Transgenic ESC clones were
selectively grown with G418 (Sigma-Aldrich). The expression of EGEP was
confirmed in beating colonies.
HCA Screening of Small Molecules for Promotion of Cardiac
Differentiation
The aMHC-GFP transgenic monkey ESCs were used for HCA screening.
During days 6–14 of cardiac differentiation, 9,600 compounds from the
chemical library were screened. On day 14, GFP fluorescence of ESCs was
measured by whole-plate scanning, using the MetaMorph imaging system
(Molecular Devices). See the Extended Experimental Procedures for detailed
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Figure 5. Cardiac Differentiation in Serum-free Defined Medium or in Serum-Containing Medium Using Small Molecules that Regulate
WNT Signaling
(A) A scheme of cardiac differentiation usingWNT signaling regulators. In the early phase of differentiation (days 0–3), precultured hPSC aggregates were cultured
in serum-free IMDM-based medium or serum-containing medium, including 0.4%–2% albumin and GSK3b inhibitors (2 mM BIO and 4 mM CHIR) on gelatin or
laminin211-coated dishes. In the middle phase (days 3–9), cells were cultured in medium with 10 mM KY02111 (KY), or 10 mM KY and 10 mM XAV939 (KY+XAV).
Beating cardiac colonies usually emerged between day 8 and day 10. In the late phase (days 15–30), cardiac colonies were cultured in defined medium without
WNT signaling regulators as floating colonies.
(B) The effects of CHIR and BIO on IMR90-1 iPSC-derived cardiac differentiation under serum/cytokine-free condition. DMSO, CHIR, BIO, or BIO along with 4 mM
CHIR (BIO+CHIR4 mM) were added in early phase, and 10 mMKY in middle phase. The number of beating colonies was examined on day 30. Mean ± SEM; n = 3.
*p < 0.05 for Student’s t test comparing to treatment of 4 mM CHIR alone.
(C) qPCR gene expression analysis of IMR90-1 hiPSCs treated with CHIR and BIO under serum-free condition. Total RNA was extracted from differentiated cells
on day 3 of cardiac differentiation after 4 mM CHIR+2 mM BIO or DMSO treatment. Mean ± SEM; n = 3. *p < 0.05, **p < 0.01 for Student’s t test.
(D) Proportion of cTnT-positive cells under serum-free and serum-containing conditions. Cardiac differentiation was carried out according to (A), using medium
with 20% serum (FBS) or 1%–2% BSA (Alb). The proportion of cTnT-positive cells was measured by MetaMorph software. Mean ± SEM; n = 3.
(E) cTnT immunostaining of differentiated cells under serum-containing (FBS) and serum-free (Alb) conditions. Red indicates cTnT staining; blue indicates DAPI
staining. Scale bar, 100 mm.
(F) Representative flow cytometry data for cTnT-positive cells induced by DMSO, KY, or KY+XAV in serum-free (Alb) medium. Red indicates cTnT-positive
cardiomyocytes. Gray indicates negative controls without the primary antibody. A total of 30,000 cells were measured in each sample by FACSCanto II.
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Cardiac Differentiation in Serum-Containing Medium
Confluent hESCs and hiPSCs were enzymatically detached and transferred
into Petri dishes (BD BioSciences) with ESC Culture Medium (ReproCELL,
Japan). Cells were held in suspension culture for 8–24 hr to form aggregates
(0.3–1 mm in diameter). Following suspension culture, cell aggregates were
allowed to attach to culture dishes (3–10 3 105 cells/cm2) in cardiac dif-
ferentiation medium: IMDM (Sigma-Aldrich) containing 20% FBS (GIBCO),
1% MEM nonessential amino acid solution (Sigma-Aldrich), 1% penicillin-
streptomycin (GIBCO), 2 mM L-glutamine (Sigma-Aldrich), 0.001% 2-mercap-
toethanol (GIBCO), and 0.005 N NaOH, with 10 ng/ml BMP4 (R&D Systems).
The medium was changed to cardiac differentiation medium with KY02111
and/or other WNT inhibitors added on day 3 (hiPSC lines) or day 4 (human
or monkey ESC lines): XAV939 (Wako, Japan); IWP-2 (Santa Cruz Biotech-
nology); IWR-1 (Merck4Biosciences); IGFBP4; Dkk1; and the mixture of
bFGF, BMP4, VEGF, DKK1, and Activin A (Yang et al., 2008). The cytokines
were obtained from R&D Systems. Medium was changed every 2–3 days;
KY02111 and other WNT inhibitors were added until day 9 for hiPSC lines
and the monkey ESC line or day 14 for hESC lines. On day 15, cardiac cell
colonies on dishes were incubated with protease solution (0.1% collagenase
type I, 0.25% trypsin, 1 U/ml DNase I, 116 mM NaCl, 20 mM HEPES,
12.5 mM NaH2PO4, 5.6 mM glucose, 5.4 mM KCl, and 0.8 mM MgSO4
[pH 7.35]) for 0.5–2 hr, until all cardiac colonies were detached. The detached
cardiac colonies were transferred into 15 ml tubes with fresh cardiac differen-
tiation medium and then the supernatant was removed by aspiration. The
cardiac colonies were transferred into Ultra-low culture dishes (Corning) or
6-well plates (Corning) in cardiac differentiation medium without both serum
and NaOH. The floating cardiac colonies were maintained for more than
1 month, and the media were changed every 5 days. A differentiation method
of mouse ESC (R1 line) was carried out as previously described by Yuasa et al.
(2005), and KY02111 was added during days 3–6. Beating colonies were
counted on day 9.
Cardiac Differentiation in Serum-free and Defined Medium
Human PSCs were precultured using serum-free cardiac differentiation
medium (see below) without chemicals in Petri dishes as described above,
and then cell aggregates were allowed to attach to culture dishes coated
with gelatin (Sigma-Aldrich) or human laminin211 (BioLamina, Sweden) at
3–10 3 105 cells/cm2, in serum-free cardiac differentiation medium: IMDM
containing 1% MEM nonessential amino acid solution, 1% penicillin-
streptomycin, 2 mM L-glutamine, 0.5 mM L-carnitine (Sigma-Aldrich),
0.001% 2-mercaptoethanol, and 1%–2% BSA (Wako) or 0.4% human serum
albumin (Sigma-Aldrich), with 4 mM CHIR (Axon) and 2 mM BIO (Calbiochem).
On days 3–9, 10 mM KY02111 and/or other WNT inhibitors (XAV939 and/or
IWP-2) were added to cell cultures, and the medium was changed every
2 days. On day 15, the cardiac colonies were incubated with the protease
solution without collagenase for 5–10 min, until all colonies were detached.
The cardiac colonies were transferred to Ultra-low culture 6-well plates with
serum-free cardiac differentiation medium including 0.1% albumin. The
floating cardiac colonies were maintained for more than 1 month, and the
media were changed every 5 days.
Immunostaining and Flow Cytometry
Cardiomyocytes derived from hPSCs were fixed with 4% paraformaldehyde
and then incubated with primary antibodies and secondary antibodies. Nuclei
were visualized by DAPI. The number of immunopositive cells was counted
from three random areas, using the MetaMorph imaging system. Approxi-
mately 1,000 DAPI-stained cells were used to calculate the proportion of
immunopositive cells. For flow cytometry, cells treated with antibodies were
analyzed using a FACSCanto II Flow Cytometer (BD Biosciences). Data were
analyzed using FACSDiva software (BD Biosciences). See the Extended(G) The number of beating colonies and total number of cardiomyocytes in serum-
cells per well were added to a 6-well plate. Red bars show cardiomyocyte number
ratio of cTnT-positive cells. Both the number of beating colonies and the total nu
medium (Alb) than in serum-containing medium (FBS). Mean ± SEM; n = 4. *p <
See also Movie S1.
Cell ReExperimental Procedures for detailed procedures and antibodies used in
this study.
Microarray Experiments
IMR90-1 iPSCs were cultured in cardiac differentiation medium containing
serum. On day 3, cells were treated with 10 mM KY02111 or 0.1% DMSO
for 0, 12, or 24 hr. Nontreated cells (0 hr), cells treated with KY02111 for
12 hr (KY12hr) or 24 hr (KY24hr), and cells treated with 0.1% DMSO for
12 hr (DMSO12hr) or 24 hr (DMSO24hr) were used for microarray analysis
using the Human Gene 1.0 ST array (Affymetrix). For analysis of Distant
Regulating Elements of co-regulated genes (DiRE analysis), all downregulated
genes (based on the KY12hr/DMSO12hr ratio) were analyzed using the
web-based program (http://dire.dcode.org/) (Gotea and Ovcharenko, 2008).
See the Extended Experimental Procedures for detailed procedures.
Quantitative RT-PCR
Total RNA (0.5 mg) was subjected to cDNA synthesis using the SuperScript III
Reverse Transcriptase (Invitrogen). Quantitative RT- PCR was performed
using SYBER Green PCR Master Mix on a 7500 Real-Time PCR System
(Applied Biosystems). Total RNA from human adult heart tissue (BioChain)
was used to evaluate the expression levels of cardiac marker genes for cardi-
omyocytes derived from hPSCs. All values were normalized with respect to
GAPDH expression level and expressed relative to the corresponding values
in human adult hearts (100%). All of the primer sets are listed in Table S2.
TOPflash Assay
IMR90-1 hiPSCs were cultured in the serum-containing differentiation culture.
HEK293 and SW480 cells were cultured in 10% FBS-DMEM and Leibovitz’s
L-15 medium (GIBCO), respectively. Cells were transfected with TOPflash
plasmid (Millipore). After 24 hr, KY02111, XAV939, or IWP-2 was added to
the medium, along with either 60 ng/ml of mouse Wnt3a (Wako) or 3 mM
BIO. Luciferase activities were measured 48 hr after transfection. See the
Extended Experimental Procedures for detailed procedures.
Patch-Clamp Recordings
Data from the whole-cell patch-clamp configuration were recorded from
spontaneously beating cells, using a HEKA EPC10 amplifier (HEKA Instru-
ments). In some experiments, cells were treated with 0.1 mM E4031, 4 mM
Chromanol293B, 4 mM zatebradine, 1 mM TTX, or 4 mM nifedipine for 5 min.
The inhibitors were obtained from Sigma-Aldrich. See the Extended
Experimental Procedures for detailed procedures.
QT Interval Prolongation Assay
ECG-like waves of KY-CMs were recorded using MEA dishes and an MEA
amplifier (Multi Channel Systems, Germany). Beating rate, Na+ amplitude,
K+ amplitude, and Na+-K+ interval were analyzed by LabChart software v7
(ADInstruments, Australia). See the Extended Experimental Procedures for
detailed procedures.
Electron Microscopy
The hiPSC-derived cardiomyocytes were fixed and then embedded in Araldite
502 resin (Polysciences,Warrington, PA, USA). The ultrathin sections (60 nm)
were observed by conventional TEM (JEOL JEM1400, Japan). See the
Extended Experimental Procedures for detailed procedures.
Statistical Analysis
Each experiment was independently performed three or more times (nR 3). All
results were expressed as mean ± SEM. Unpaired two-tailed Student’s
t tests were used to compare mean values of measurements from different
treatments. Differences were considered significant at p < 0.05.free and defined culture conditions. On day 0 of differentiation, 63 106 IMR90-1
s in each well, calculated by multiplying total cell numbers of all colonies by the
mber of cardiomyocytes induced by KY or KY+XAV increased more in defined
0.05, **p < 0.01 for Student’s t test.
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Figure 6. Cardiac Differentiation of Several hPSC Lines in Cytokine-free, Serum-free, and Xeno-free Defined Condition
(A) hESC lines (H1, H9, and KhES-3) and hiPSC lines (IMR90-1, RCHIPC003, and 253G1) were highly efficiently differentiated into cardiomyocytes under xeno-
free and cytokine-free condition as Figure 5A except XAV939 concentration (2 mM instead of 10 mM). Mean ± SEM. n, the number in parentheses.
(B) Representative flow cytometry data of cTnT-positive cells generated from each hPSC line. Red indicates cTnT-positive cardiomyocytes. Gray indicates
negative control without the primary antibody. A total of 30,000 cells were measured in each sample by FACSCanto II.
(C) The immunostaining of aActinin (red) in IMR90-1 hiPSC-derived cardiomyocytes. Images were deconvolved using theMetaMorph software. Scale bar, 30 mm.
DAPI is in blue.
(D) Transmission electron microscopic images of 253G1 hiPSC-derived cardiomyocytes. In parallel sections (left and upper-right images), mitochondria (black
arrowheads), myofibrils, with Z bands (white arrowheads), and candidate structures of intercalated disks with desmosomes (white arrows) were observed. In
the cross section (bottom right image), sarcoplasmic reticula around myofibrils represented by thin actin and thick myosin filaments were found (black
arrows).
(E) Gene expression analysis of IMR90-1 hiPSC-derived cardiomyocytes. Total RNA was extracted from cells on days 15 and 30 of cardiac differentiation. The
expression levels of cardiac marker genes (aMHC, aActinin, andNKX2.5) and channel genes (HCN4,Nav1.5,Cav1.2,Cav3.2,HERG1b, and KCNQ1) were nearly
equal to the gene expression levels of adult heart tissue, which was considered to be 100% (mean ± SEM, n = 3).
See also Figure S6 and Movie S2.
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